Access Vascular is revolutionizing vascular access with its innovative HydroPICC® and HydroMID® devices, which utilize the proprietary MIMIX® technology. This advanced hydrophilic biomaterial is specifically designed to mitigate common complications associated with vascular access, such as thrombosis, which is a leading cause of device failure. Clinical data indicates that these devices demonstrate a statistically significant reduction in complications compared to traditional polyurethane catheters, with an impressive 97% reduction in thrombus accumulation on their surfaces. By minimizing the need for catheter replacements, Access Vascular's solutions not only enhance patient experience by reducing unnecessary needle sticks but also offer substantial cost savings for healthcare facilities.

The MIMIX® technology employed in Access Vascular's devices allows for a unique interaction with the body's natural chemistry. Upon hydration, the material becomes consistently hydrophilic and lubricious, effectively camouflaging the catheter within the body and repelling protein adsorption. This hydrophilic nature helps to prevent the foreign body response typically triggered by catheter insertion, thereby reducing the cascade of complications that can arise. By addressing these critical issues, Access Vascular aims to improve the overall efficacy and safety of vascular access procedures, ultimately benefiting both patients and healthcare providers.

United States

Access Vascular is offering our suite of vascular access solutions designed to help clinicians address common catheter complications that afflict patients while helping save hospitals time and money.

Access Vascular

Company Details